Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2013 Nov 5;8(11):e79150.
doi: 10.1371/journal.pone.0079150. eCollection 2013.

PAI-1 -675 4G/5G polymorphism in association with diabetes and diabetic complications susceptibility: a meta-analysis study

Kuanfeng Xu  1 , Xiaoyun Liu, Fan Yang, Dai Cui, Yun Shi, Chong Shen, Wei Tang, Tao Yang
Affiliations
Meta-Analysis

PAI-1 -675 4G/5G polymorphism in association with diabetes and diabetic complications susceptibility: a meta-analysis study

Kuanfeng Xu et al. PLoS One. .

Abstract

A meta-analysis was performed to assess the association between the PAI-1 -675 4G/5G polymorphism and susceptibility to diabetes mellitus (DM), diabetic nephropathy (DN), diabetic retinopathy (DR) and diabetic coronary artery disease (CAD). A literature-based search was conducted to identify all relevant studies. The fixed or random effect pooled measure was calculated mainly at the allele level to determine heterogeneity bias among studies. Further stratified analyses and sensitivity analyses were also performed. Publication bias was examined by the modified Begg's and Egger's test. Twenty published articles with twenty-seven outcomes were included in the meta-analysis: 6 studies with a total of 1,333 cases and 3,011 controls were analyzed for the PAI-1 -675 4G/5G polymorphism with diabetes risk, 7 studies with 1,060 cases and 1,139 controls for DN risk, 10 studies with 1,327 cases and 1,557 controls for DR and 4 studies with 610 cases and 1,042 controls for diabetic CAD risk respectively. Using allelic comparison (4G vs. 5G), the PAI-1 -675 4G/5G polymorphism was observed to have no significant association with diabetes (REM OR 1.07, 95% CI 0.96, 1.20), DN (REM OR 1.10, 95% CI 0.98, 1.25), DR (REM OR 1.09, 95% CI 0.97, 1.22) or diabetic CAD risk (REM OR 1.07, 95% CI 0.81, 1.42), and similar results were obtained in the dominant, recessive and co-dominant models. Our meta-analyses suggest that the PAI-1 -675 4G/5G polymorphism might not be a risk factor for DM, DN, DR or diabetic CAD risk in the populations investigated. This conclusion warrants confirmation by further studies.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Pooled ORs for the association between the PAI-1 -675 4G/5G polymorphism (4G vs. 5G) and susceptibility to diabetes.
The area of the squares reflects the study-specific weight. The diamond shows the summary fixed-effects OR estimate from 6 studies.
Figure 2
Figure 2. Pooled ORs for the association between the PAI-1 -675 4G/5G polymorphism (4G vs. 5G) and susceptibility to diabetic nephropathy.
The area of the squares reflects the study-specific weight. The diamond shows the summary fixed-effects OR estimate from 7 studies.
Figure 3
Figure 3. Pooled ORs for the association between the PAI-1 -675 4G/5G polymorphism (4G vs. 5G) and susceptibility to diabetic retinopathy.
The area of the squares reflects the study-specific weight. The diamond shows the summary fixed-effects OR estimate from 10 studies.
Figure 4
Figure 4. Pooled ORs for the association between the PAI-1 -675 4G/5G polymorphism (4G vs. 5G) and susceptibility to diabetic coronary artery disease.
The area of the squares reflects the study-specific weight. The diamond shows the summary random-effects OR estimate from 4 studies.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Vassalli JD, Sappino AP, Belin D (1991) The plasminogen activator/plasmin system. J Clin Invest 88: 1067-1072. doi:10.1172/JCI115405. PubMed: 1833420. - DOI - PMC - PubMed
    1. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM (2002) Insulin Resistance Atherosclerosis Study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 51: 1131-1137. doi:10.2337/diabetes.51.4.1131. PubMed: 11916936. - DOI - PubMed
    1. Festa A, Williams K, Tracy RP, Wagenknecht LE, Haffner SM (2006) Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes. Circulation 113: 1753-1759. doi:10.1161/CIRCULATIONAHA.106.616177. PubMed: 16585388. - DOI - PubMed
    1. Gori AM, Marcucci R, Fatini C, Gensini F, Sticchi E et al. (2004) Impaired fibrinolysis in retinal vein occlusion: a role for genetic determinants of PAI-1 levels. Thromb Haemost 92: 54-60. PubMed: 15213845. - PubMed
    1. Steinberger J, Daniels SR (2003) Obesity, insulin resistance, diabetes, and cardiovascular risk in children: an American Heart Association scientific statement from the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). Circulation 107: 1448-1453. doi:10.1161/01.CIR.0000060923.07573.F2. PubMed: 12642369. - DOI - PubMed

Publication types

MeSH terms

Substances